发布日期:2025/4/22 14:33:00

Nasal delivery of a CRMP2-derived CBD3 adenovirus improves cognitive function and pathology in APP/PS1 transgenic mice

Baochang Qi 1, Yu Yang2, Yingying Cheng2 , Di Sun3 , Xu Wang2 , Rajesh Khanna4,5* and Weina Ju2*

Abstract: Calcium dysregulation is a key pathological event in Alzheimers disease (AD). In studying approaches to mitigate this calcium overload, we identified the collapsin response mediator protein 2 (CRMP2), an axonal guidance protein that participates in synapse dynamics by interacting with and regulating activity of N-methyl-D-aspartate receptors (NMDARs). We further identified a 15 amino acid peptide from CRMP2 (designated CBD3, for calcium-binding domain 3), that reduced NMDAR-mediated Ca2+ influx in cultured neurons and post-synaptic NMDAR-mediated currents in cortical slices. Whether targeting CRMP2 could be therapeutically beneficial in AD is unknown. Here, using CBD3, we tested the utility of this approach. Employing the APP/PS1 mouse model of AD which demonstrates robust pathophysiology including Aβ142 deposition, altered tau levels, and diminished cognitive functions, we asked if overexpression of CBD3 could rescue these events. CBD3 was engineered into an adenoassociated vector and nasally delivered into APP/PS1 mice and then biochemical (immunohistochemistry, immunoblotting), cellular (TUNEL apoptosis assays), and behavioral (Morris water maze test) assessments were performed. APP/PS1 mice administered adeno-associated virus (AAV, serotype 2) harboring CBD3 demonstrated: (i) reduced levels of Aβ142 and phosphorylated-tau (a marker of AD progression), (ii) reduced apoptosis in the hippocampus, and (iii) reduced cognitive decline compared with APP/PS1 mice or APP/PS1 administered a control virus. These results provide an instructive example of utilizing a peptide-based approach to unravel protein-protein interactions that are necessary for AD pathology and demonstrate the therapeutic potential of CRMP2 as a novel protein player in AD.

详情请见:https://doi.org/10.1186/s13041-020-00596-3

在该研究中圣尔生物通用型ECL发光液用于Western blotting实验

Western blotting

The band was visualized by the ECL (Share-Bio; SB-WB012).

上一篇:圣尔通用型ECL发光液助力科研-Wenfang Xiong等,南京大学附属鼓楼医院,Cell Death and Disease IF:9.969 下一篇:圣尔通用型ECL发光液助力科研-Zhengming Yang等,浙大附属第二医院,Journal of Orthopaedic Surgery and Research, IF:2.8

相关产品

产品编号 产品名称 规格(ml) 目录价(元)
SB-WB012 lumiQ通用型ECL发光液 lumiQ ECL ElectroChemiluminescence;enhanced chemiluminescent (ECL) horseradish peroxidase (HRP) substrate kit 250ml+250ml
6*(250ml+250ml)
50ml+50ml
5ml+5ml